General description
|
16 (100)
|
“The DNA test(s) detect small differences (variants) in DNA which can affect the way drugs work and are metabolized in your body and/or detect potential side effects”
|
Purpose of test
|
14 (91)
|
“Pharmacogenomics testing determines how genetic makeup affects my response to medication”
|
Genetic counseling recommendation
|
10 (73)
|
“Genetic counseling is recommended prior to, as well as following genetic testing”
|
Potential results/meaning of results
|
11 (73)
|
“DNA results may: indicate whether or not you have this condition or are at risk for developing this condition. Indicate whether or not you are a carrier for this condition, predict that another family member has or is at risk for developing this condition, predict that another family member is a carrier of this condition”
|
Description of disease being tested
|
16 (100)
|
“Genotyping of CYP2C9, CYP2C19 and VKORC1 for metabolism status to determine proper initial dosage of warfarin to avoid bleeding events and overdose”
|
Disclosure of results
|
15 (91)
|
“Because of the complexity of genetic testing and the important implications of the test results, results will be reported only through a physician, genetic counselor or other identified healthcare provider”
|
Storage/destruction of sample
|
16 (100)
|
“The sample will be destroyed at the end of the testing process or not more than 60 days after the sample was taken…”
|
Medical risks and benefits |
11 (73) |
“Side effects of having blood drawn are uncommon, but may include dizziness, fainting, soreness, pain, bleeding, bruising and, rarely, infection. Other risks that may be experienced as a result of this testing include: related emotional issues, impact on life – changing decisions, potential genetic discrimination (e.g., in employment and insurance areas) and loss of confidentiality” |